RxDoctor Payments Data

Susan Suen, NP

Family · Rialto, CANPI 1013425818

Payments from drug & device makers

$501in general payments, 2019–2025

Across 18 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$189
  • Pfizer$61
  • Novo Nordisk$48
  • Bayer$41
  • Novartis$40
  • Ardelyx, Inc.$35
  • plus $86 from 4 others

What the payments were for

  • Food & beverage$501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$501 in reported general payments places this provider in the 60th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$1,787
Medicare patients
13
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast20$91,451
EntrestoSacubitril/Valsartan25$40,643
TrulicityDulaglutide16$23,887
OzempicSemaglutide19$23,479
JanuviaSitagliptin Phosphate15$18,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,067
FarxigaDapagliflozin Propanediol16$16,770
TradjentaLinagliptin19$16,760
VemlidyTenofovir Alafenamide12$16,492
EliquisApixaban11$15,024
JardianceEmpagliflozin17$14,987
KerendiaFinerenone12$10,646
VascepaIcosapent Ethyl11$9,677
LinzessLinaclotide14$9,075
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$40$40,64325 claims
Novo NordiskOzempic$48$23,47919 claims
MerckJanuvia$23$18,06515 claims
GSKTrelegy Ellipta$18$17,06719 claims
PfizerEliquis$61$15,02411 claims
BayerKerendia$41$10,64612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,634 family providers in California.

Other family in Rialto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →